This article provides general policy analysis and educational information only. It does not constitute medical or legal advice. PBS criteria and TGA approvals are subject to change — consult a qualified medical practitioner regarding individual treatment decisions.

Medicare and PBS Reform for Obesity Treatment: What Australia Needs to Do

Australia is experiencing an obesity crisis that its public health system is structurally unprepared to treat. More than two-thirds of Australian adults are living with overweight or obesity. Obesity-related conditions — type 2 diabetes, cardiovascular disease, sleep apnoea, osteoarthritis, and certain cancers — account for an estimated $11.8 billion in direct healthcare costs annually, with indirect productivity losses adding substantially to that figure. Effective pharmacological treatments for obesity now exist. The clinical evidence for their efficacy is among the strongest in modern endocrinology. And yet access to these treatments in Australia remains severely constrained by a PBS framework that has not kept pace with either the science or the scale of the problem.

This is a policy failure with direct, measurable consequences. Australians who cannot afford $200–250 per month for private semaglutide prescriptions — the real-world cost of Ozempic used off-label for weight management — go without treatment that could materially reduce their risk of heart attack, stroke, and diabetes progression. Those who can afford it access the same medication that is available on the PBS to patients with type 2 diabetes, but at fifteen to twenty times the subsidised price. The resulting system is not clinically rational. It is not economically efficient. And it is not equitable.

The Coalition for Better Health's position is unambiguous: Australia needs substantive PBS reform for obesity pharmacotherapy. This article makes the case.

The Current State of PBS Coverage for Obesity Medications

What Is and Is Not Subsidised

The PBS landscape for obesity pharmacotherapy in 2026 is characterised by a narrow approval framework that was designed for a disease model the clinical community has largely moved beyond.

Semaglutide (Ozempic / Wegovy): Ozempic (semaglutide 0.5mg, 1mg, 2mg) has been PBS-listed since 2020 for the treatment of type 2 diabetes, with a subsidised price of approximately $30–45 per month under the general benefit. The same molecule — semaglutide — in the higher-dose formulation marketed as Wegovy (2.4mg weekly) received TGA approval for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity, in 2023. Wegovy achieved PBS listing in 2026, but with restrictive criteria: patients must have a BMI ≥35 with established cardiovascular disease or type 2 diabetes, must have failed at least six months of intensive lifestyle intervention under specialist supervision, and must be managed by an endocrinologist or bariatric physician. The PBS-subsidised price is approximately $85–95 per month under this listing.

For the substantial majority of patients who would clinically benefit — those with BMI 30–34.9, those without a formal T2D or CVD diagnosis, those without access to specialist care or who cannot demonstrate six months of supervised lifestyle intervention — Wegovy remains unsubsidised. Ozempic, used off-label for weight loss without a T2D diagnosis, is not PBS-claimable, and pharmacies fill it at private prices of $200–250 per month.

Dulaglutide (Trulicity) and liraglutide (Saxenda / Victoza): Liraglutide (Victoza) is PBS-listed for T2D only. Saxenda (liraglutide 3mg), TGA-approved for weight management, has no PBS listing. Dulaglutide is listed for T2D only.

Tirzepatide (Mounjaro): Tirzepatide — a dual GIP/GLP-1 receptor agonist that has demonstrated superior weight loss outcomes to semaglutide in head-to-head trials — received TGA approval in Australia in 2024. It has no PBS listing for any indication as of mid-2026.

Orlistat: The sole obesity-specific medication with any PBS history, orlistat (Xenical) was removed from the PBS in 2012 due to low uptake. It is available over-the-counter at private cost (approximately $90–130 per month) with modest efficacy compared to the newer GLP-1 class.

The net result is a system in which the most effective pharmacological interventions for obesity — GLP-1 receptor agonists and dual agonists — are accessible on the PBS only to patients with established T2D or CVD, and even then only through narrow criteria. For most Australians with clinically significant obesity, public subsidy does not exist.

The Cost Barrier in Practice

The practical impact of this coverage gap is substantial and well-documented. A 2024 survey by the Royal Australian College of General Practitioners found that more than 60% of GPs identified cost as the primary barrier to initiating GLP-1 therapy in patients they assessed as clinically appropriate candidates. A patient paying $220 per month for private semaglutide spends $2,640 annually — a sum that represents more than two weeks of full-time minimum wage earnings. For lower-income Australians, this cost is prohibitive. For many middle-income households, it represents a meaningful sacrifice.

The cost barrier is not uniformly distributed. It falls hardest on exactly those populations where obesity prevalence is highest: lower socioeconomic groups, regional and rural communities, First Nations Australians, and recent migrants. The Australian Bureau of Statistics data consistently shows an inverse gradient between socioeconomic position and obesity prevalence. The current PBS framework systematically denies subsidised access to pharmacotherapy to the populations that bear the greatest burden of the disease.

The Clinical Evidence That Justifies Reform

GLP-1 Receptor Agonists: What the Trials Show

The clinical evidence base for GLP-1 receptor agonists in obesity management is now among the most robust in pharmacology. The STEP trial program for semaglutide — comprising STEP 1 through 5, with follow-up data extending beyond two years — demonstrated mean weight loss of 14.9% from baseline at 68 weeks in STEP 1, compared to 2.4% in the placebo group. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity, without requiring a diabetes diagnosis for enrolment. This cardiovascular outcome data is directly policy-relevant: it demonstrates that obesity pharmacotherapy is not merely cosmetic or quality-of-life intervention — it reduces hard clinical endpoints.

Tirzepatide data from the SURMOUNT trial program is, if anything, more striking. SURMOUNT-1 demonstrated mean weight loss of 20.9% at 72 weeks in the highest dose group. SURMOUNT-4 demonstrated that continued treatment is necessary to maintain benefit, with patients who discontinued experiencing substantial weight regain — a finding with important implications for PBS listing duration criteria.

For a comprehensive overview of the mechanisms and clinical evidence base for GLP-1 receptor agonists across metabolic conditions, see our GLP-1 receptor agonists and metabolic health research overview.

The Chronicity Evidence

A critical — and often politically inconvenient — finding from the GLP-1 trial literature is that obesity pharmacotherapy, like antihypertensive or lipid-lowering therapy, needs to be continued long-term to maintain benefit. The STEP 4 extension trial demonstrated that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year. This is not a product failure — it reflects the underlying biology of adiposity regulation, in which the hypothalamic set-point for body weight is actively defended. It does, however, have direct PBS policy implications: listing criteria that impose treatment duration caps, or that require periodic re-justification through re-demonstration of weight loss thresholds, are not aligned with the evidence on how this class of medication works.

The clinical community's emerging consensus — articulated by Obesity Australia, the Endocrine Society of Australia, and increasingly by the Australian Diabetes Society — is that obesity should be treated as a chronic relapsing condition requiring long-term management, not a short-term intervention target. PBS framework design needs to reflect this consensus.

International Comparisons: What Other Systems Are Doing

NHS England

England's NHS provides one of the most instructive comparisons. NHS England introduced a phased rollout of semaglutide (Wegovy) for weight management beginning in 2023, initially through specialist tier services (Tier 3 weight management programmes) and expanding progressively. The NHS framework acknowledges the supply constraint created by high demand and the need for managed rollout, but the underlying policy direction is toward broad, equitable access. The National Institute for Health and Care Excellence (NICE) technology appraisal TA875 approved semaglutide for adults with at least one weight-related comorbidity and BMI ≥35 (or ≥30 in certain higher-risk groups), with a two-year treatment limit in the specialist setting.

The NHS is also piloting primary care-based prescribing models to reduce the specialist bottleneck — a direct response to the access barrier created by specialist-only prescribing requirements.

Canada

Health Canada approved semaglutide (Wegovy) for chronic weight management in 2021. Provincial drug plan coverage varies significantly, but several provinces — including Ontario through its Exceptional Access Programme and British Columbia through PharmaCare — provide coverage for patients meeting specified BMI and comorbidity criteria. The Canadian Obesity Network has advocated for consistent national coverage, framing inconsistent provincial coverage as an equity issue.

United States

The US presents a more complex picture due to the fragmented insurer model, but the policy direction at the federal level is significant. The Biden administration's proposed rule to require Medicare and Medicaid coverage of GLP-1 obesity medications reflects a policy determination that excluding obesity pharmacotherapy from public coverage is clinically and economically indefensible. Several major US private insurers have moved to cover GLP-1 medications for obesity without a T2D requirement.

The international direction of travel is clear: systems that have reviewed the evidence are moving toward broader, not narrower, coverage of obesity pharmacotherapy.

The Economic Argument for Expanded PBS Coverage

Cost of Obesity vs Cost of Treatment

The economic argument for expanded PBS coverage is compelling and has been inadequately ventilated in Australian policy discussions. The AIHW's 2022 burden of disease analysis estimated that overweight and obesity were responsible for 8.4% of Australia's total burden of disease, making it one of the leading modifiable risk factor contributions to disease burden. The direct healthcare costs — hospitalisation, specialist services, pharmaceutical treatment of downstream conditions — are estimated at $11.8 billion annually, with productivity losses adding a further $5.6 billion.

By contrast, the PBS cost of subsidising semaglutide at a population scale can be modelled with reasonable precision from the trial data and existing subsidy levels. A conservative estimate, based on the Wegovy private price and a realistic take-up rate among eligible patients, suggests PBS expenditure of $2–4 billion annually for broad-access listing — less than one-third of the direct healthcare cost attributable to obesity, and a fraction of the total economic burden. The Australian Government's Cost-Effectiveness threshold for PBS listings is a cost per QALY (quality-adjusted life year) of approximately $45,000–$75,000. Health economic analyses of semaglutide for weight management in populations with cardiovascular risk factors consistently come in below this threshold, particularly when downstream cardiovascular event reduction from SELECT is incorporated.

The Pharmaceutical Benefits Advisory Committee (PBAC) has access to this modelling. The question of whether the economic case has been fully weighted — against the political risks of appearing to subsidise what is still sometimes framed as a lifestyle medication — is a legitimate one for public policy scrutiny.

The Downstream Savings Argument

Beyond the direct cost-effectiveness modelling, there is a downstream savings argument that is harder to quantify but important. Sustained weight loss of 10–15% in patients with pre-diabetes reduces progression to type 2 diabetes by approximately 50–60% (DiRECT trial and related evidence). Given that T2D management costs the PBS more than $1 billion annually and growing, prevention through obesity pharmacotherapy has value that extends beyond the immediate treatment indication. Similarly, reductions in cardiovascular events — hospitalisation, CABG, stroke — represent avoided costs that should feature in PBAC modelling.

The Equity Argument

The equity dimension of current PBS coverage is straightforward and morally serious. Australia's public health system is predicated on the principle that access to evidence-based treatment should not depend on ability to pay. That principle is realised imperfectly in practice — private health insurance creates a parallel tier for elective procedures — but it is foundational to Medicare's legitimacy.

The current PBS framework for obesity pharmacotherapy creates a two-tiered system in which wealthy Australians access effective treatment at private cost, while lower-income Australians — who bear a disproportionate burden of obesity and its complications — are excluded. A patient with type 2 diabetes pays $30–45/month for semaglutide on the PBS. A patient with class II obesity (BMI 35–39), without a diabetes diagnosis, pays $200–250/month for the same drug, or goes without. The clinical distinction is real but the treatment benefit is comparable. The equity implication is significant.

Obesity Australia has framed this directly: the PBS gap in obesity pharmacotherapy is creating a "pharmacological equity crisis" in which the patients most in need of treatment are least able to access it. The Coalition for Better Health endorses this framing.

For a detailed analysis of the scale of Australia's obesity challenge and the evidence base underpinning the need for systemic reform, see our obesity crisis in Australia evidence overview.

TGA-Approved Medications Awaiting Adequate PBS Access

Beyond semaglutide and tirzepatide, several compounds are either TGA-approved or in late-stage regulatory consideration and warrant PBS pathway planning:

Tirzepatide (Mounjaro): TGA-approved for T2D in 2024; the obesity indication is in regulatory review. SURMOUNT trial data supports efficacy superior to semaglutide. PBS listing for the obesity indication should be a PBAC priority once TGA approval is granted.

Retatrutide: A triple agonist (GIP/GLP-1/glucagon) in Phase 3 trials with preliminary data showing mean weight loss exceeding 24% — the most substantial pharmacological weight reduction ever demonstrated. Not yet TGA-approved, but the regulatory and PBS planning horizon should account for its likely arrival.

Orforglipron: An oral GLP-1 receptor agonist (non-peptide small molecule) with Phase 3 data showing meaningful weight loss. An oral formulation would substantially expand the population able to adhere to treatment. PBS planning should anticipate this class.

The pace of innovation in this space is rapid. A PBS framework that requires years of post-approval deliberation for each new agent will consistently lag the clinical evidence. A structured fast-track assessment process for obesity pharmacotherapy — analogous to the oncology pathway — is warranted.

For context on how TGA scheduling frameworks apply to peptide-based compounds in Australia, see the TGA peptide regulation guide for patients and clinicians.

For context on the policy implications of TGA rescheduling decisions for compounds like BPC-157 — and what they reveal about Australia's regulatory framework for emerging therapeutics — see the BPC-157 Schedule 4 rescheduling policy explainer.

What Reform Should Look Like: Proposed PBS Criteria

The Coalition for Better Health proposes the following framework for PBS listing reform for obesity pharmacotherapy:

Eligibility Criteria

Tier 1 (GP-prescribable):

• BMI ≥30 with at least one weight-related comorbidity (type 2 diabetes, pre-diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, NAFLD, osteoarthritis of weight-bearing joints, established cardiovascular disease)
• OR BMI ≥35 without comorbidity requirement
• Documentation of at least three months of dietary and lifestyle modification attempt (not requiring specialist supervision)
• Annual review for continuation

Tier 2 (Specialist-prescribable, GP continuable):

• BMI ≥27.5 in high-risk populations (First Nations Australians, South Asian, Southeast Asian, and Pacific Islander backgrounds where cardiometabolic risk is elevated at lower BMI)
• Complex cases requiring endocrinologist or bariatric physician assessment
• Initiation of second-line agents (tirzepatide) where first-line therapy has failed

Prescriber Framework

• GP prescribing for Tier 1 should be enabled from day one of listing — specialist-only prescribing creates an access bottleneck that disproportionately affects rural and lower-income patients
• Telehealth prescribing should be explicitly included given the geographic distribution of obesity burden in Australia
• Annual review by any prescriber, not specialist-only review, is appropriate given the chronic disease model

Continuation Criteria

• Continued PBS subsidy should not require ongoing weight loss demonstration beyond a minimum response threshold at six months (e.g., ≥5% weight loss)
• Patients who maintain weight loss or prevent weight regain should not be delisted on the basis of "insufficient ongoing response"
• Duration should not be capped — obesity pharmacotherapy is long-term management, not a short course

Safety Monitoring

• Monitoring for pancreatitis, thyroid C-cell tumour risk, and gastroparesis as per TGA product information
• Mandatory reporting to a national pharmacovigilance registry for the first five years of broad PBS listing, given the scale of population exposure anticipated

The Policy Gap and What Needs to Happen

The current policy gap is not primarily a regulatory one — TGA approval is in place for semaglutide and will follow for tirzepatide. The gap is a PBS listing and criteria gap, and the mechanism for addressing it is PBAC submission and government decision.

What needs to happen:

1. PBAC re-submission for Wegovy with expanded criteria: The current Wegovy listing criteria should be challenged through a new PBAC submission with broader eligibility and GP prescribing rights. The clinical sponsor has commercial incentive to pursue this, but PBAC submissions can also be made by clinical bodies — the Endocrine Society of Australia, Obesity Australia, and the RACGP should consider a joint submission.

2. Government policy commitment: PBAC recommendations require government acceptance. A clear government commitment to accepting a positive PBAC recommendation for broader obesity pharmacotherapy access would signal that the political barrier is removed.

3. PBS supply security: The global semaglutide shortage of 2022–2024 demonstrated that rapid PBS listing without supply security creates problems. Government should negotiate supply agreements with manufacturers as part of the listing process.

4. Equity impact assessment: All future PBAC submissions for obesity pharmacotherapy should include a mandatory equity analysis assessing differential access by socioeconomic status, geographic location, and cultural background.

5. Coordination with preventive health: PBS pharmacotherapy access should be coordinated with — not substituted for — investment in preventive health infrastructure: dietary counselling Medicare items, exercise physiology rebates, and community-based lifestyle programs.

For analysis of how metabolic syndrome — the underlying condition driving much of Australia's obesity-related disease burden — is addressed by current policy, see our metabolic syndrome public health policy analysis.

FAQ

Is Wegovy currently available on the PBS? Yes, but with restrictive criteria. As of 2026, Wegovy (semaglutide 2.4mg) is PBS-listed for adults with BMI ≥35 who also have established cardiovascular disease or type 2 diabetes, have completed at least six months of specialist-supervised lifestyle intervention, and are managed by an endocrinologist or bariatric physician. Patients who do not meet all these criteria must pay private prices.

Why is Ozempic so expensive for weight loss if it's cheap on the PBS? Ozempic is PBS-subsidised only for type 2 diabetes. Using it for weight loss without a T2D diagnosis is an off-label use that does not attract the PBS subsidy. The private cost reflects the manufacturer's wholesale price without government subsidy — approximately $200–250 per month depending on dosage and pharmacy.

What is the PBAC and how does it decide what gets listed? The Pharmaceutical Benefits Advisory Committee is the independent expert body that assesses clinical effectiveness, safety, and cost-effectiveness of medicines for PBS listing. It makes recommendations to the Minister for Health, who makes the final listing decision. Submissions can be made by pharmaceutical companies, clinical bodies, and patient organisations.

Does Medicare cover obesity treatment at all? Medicare provides some coverage for GP and specialist consultations. The Chronic Disease Management (CDM) framework provides a limited number of allied health visits annually for patients with chronic conditions, including obesity. However, pharmacotherapy for obesity is not covered through Medicare — it sits in the PBS domain, where coverage is currently narrow.

Would expanding PBS coverage for obesity medications be affordable? Health economic analyses consistently show that GLP-1 receptor agonists for obesity are cost-effective at the Australian PBS threshold when downstream cardiovascular and diabetes event reduction is incorporated. The upfront PBS cost is real, but the downstream avoided costs — reduced hospitalisation, delayed T2D onset, reduced cardiovascular events — are also substantial. The net cost to the health system of treating obesity is lower than the cost of not treating it.

What can patients do now? Patients who believe they may benefit from obesity pharmacotherapy should discuss options with their GP. For those who meet current PBS criteria, subsidised access is available. For those who do not, private prescriptions are an option where cost is manageable, and clinical trials may offer access to emerging agents. Advocacy — through patient organisations, GP submissions to PBAC, and engagement with MPs — remains the primary mechanism for systemic change.

The Coalition's Position

The Coalition for Better Health calls on the Australian Government and PBAC to:

• Expand Wegovy PBS listing criteria to BMI ≥30 with any weight-related comorbidity, or BMI ≥35 without comorbidity requirement
• Enable GP prescribing for first-line obesity pharmacotherapy from the date of expanded listing
• Commit to a fast-track PBAC assessment pathway for tirzepatide obesity indication upon TGA approval
• Remove specialist-only prescribing requirements that create geographic and socioeconomic access barriers
• Fund an equity impact analysis of current and proposed PBS obesity pharmacotherapy criteria
• Treat obesity pharmacotherapy continuation criteria in line with other chronic disease medications — without arbitrary duration caps or re-demonstration requirements

Australia has the clinical evidence, the economic case, and the institutional machinery to do better on obesity pharmacotherapy access. What has been missing is the political will to act. That is a policy choice, and like all policy choices, it has consequences — measured in avoidable disease burden, inequitable access, and a public health system that tells its most vulnerable patients that effective treatment exists but not for them.

This article reflects the Coalition for Better Health's policy analysis and advocacy position. It does not constitute medical advice. PBS criteria and TGA approvals are subject to change — verify current status with your prescriber or the Department of Health website. The Coalition for Better Health is an independent health policy and advocacy organisation.